## **AMENDMENT OF THE CLAIMS**:

## 1. (Currently amended) A compound of formula (I):

$$R^{1}$$
  $X$   $Y$   $N$   $R^{10}$   $R^{2}$   $(I)$ 

wherein:

R<sup>1</sup> represents is substituted or unsubstituted aryl;

X represents is -O- or a bond;

Y represents is  $-(CR_{na}R_{nb})_{n}$ -;

R<sub>na</sub> and R<sub>nb</sub> are each independently hydrogen or C<sub>1-6</sub>alkyl;

n is an integer from 1 to 5;

R<sup>2</sup> represents is unsubstituted or substituted aryl or unsubstituted or substituted heteroaryl;

R<sup>3</sup> represents is hydrogen or C<sub>1-6</sub>alkyl;

R<sup>10</sup> represents is hydrogen or C<sub>1-6</sub>alkyl;

and salts and solvates thereof;

with the proviso that the following compounds are excluded;

2-(4-chlorophenyl)-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-phenylacetamide;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-phenoxyacetamide;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(4-methoxyphenyl)acetamide;

2-(3-Chlorophenyl)-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-[4-(methylthio)-

-phenyl]acetamide;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-[4-(dimethylamino)-

-phenyl]acetamide compound with formic acid (1:1);

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-{4-[(dimethylamino)-

-sulfonyl]phenyl}acetamide compound with formic acid (1:1);

```
N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-[4-(methylsulfonyl)-
-phenyl]acetamide compound with formic acid (1:1)
N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(3-fluorophenyl)acetamide;
2-[3,5-bis(trifluoromethyl)phenyl]-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]-
-methyl}acetamide;
2-(2-chlorophenyl)-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide;
N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(4-fluoro-2-methylphenyl)-
-acetamide;
N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(3,4-difluorophenyl)-
-acetamide;
4-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-
-benzamide;
N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-[4-(trifluoromethyl)-
-phenyllacetamide;
N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(4-methylphenyl)acetamide;
N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(2,4-dichlorophenyl)-
-acetamide:
N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(4-fluorophenyl)acetamide;
N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(3,4-dichlorophenyl)-
-acetamide;
N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(2,5-dichlorophenyl)-
-acetamide;
N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(2,6-dichlorophenyl)-
-acetamide;
2-(4-chlorophenyl)-N-{[4-(2,3-dichlorobenzyl)morpholin-2-yl]methyl}-
-acetamide trifluoroacetate;
2-[3-(acetylamino)phenyl]-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-
-acetamide;
2-(4-acetylphenyl)-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide
trifluoroacetate;
2-(4-acetylphenyl)-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide;
N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(4-isobutyrylphenyl)acetamide
trifluoroacetate;
```

methyl 4-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-

```
-benzoate trifluoroacetate;
```

- methyl 4-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-benzoate;
- 2-(4-cyanophenyl)-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide trifluoroacetate;
- 2-(4-cyanophenyl)-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide;
- $2\hbox{-}(4\hbox{-}chlorophenyl)\hbox{-}N\hbox{-}\{[4\hbox{-}(3,4\hbox{-}dichlorobenzyl)morpholin\hbox{-}2\hbox{-}yl]methyl}\} propanamide;$
- N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(3-fluoro-4-hydroxyphenyl)-acetamide trifluoroacetate;
- N-{[(2R)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-[4-(methylsulfonyl)-phenyl]acetamide;
- N-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-[4-(methylsulfonyl)-phenyl]acetamide;
- $N-\{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl\}-2-\{4-[(4-methylpiperazin-ne$
- -1-yl)carbonyl]phenyl}acetamide;
- $4-[2-(\{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl\}amino)-2-oxoethyl]-N-dichlorobenzyl)morpholin-2-yl]methyl$
- -[2-(dimethylamino)ethyl]benzamide;
- 4-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-
- -N,N-dimethylbenzamide;
- 4-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-N-
- -ethylbenzamide;
- 4-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-N-
- -(2-hydroxyethyl)benzamide;
- $N-\{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl\}-2-[4-(morpholin-4-yl-n-2-yl-$
- -carbonyl)phenyl]acetamide;
- N-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-{3-[(dimethylamino)--sulfonyl]phenyl}acetamide;
- N-{[(2R)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-{4-[(dimethylamino)-sulfonyl]phenyl}acetamide;
- N-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-{4-[(dimethylamino)-sulfonyl]phenyl}acetamide;
- 4-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-N-methylbenzamide;
- 4-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-N-

-phenyl]acetamide;

```
-isopropylbenzamide;
N-cyclopropyl-4-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-
-oxoethyl]benzamide;
4-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-N-(2-
-methoxyethyl)benzamide;
N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(4-nitrophenyl)acetamide;
N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(3-nitrophenyl)acetamide;
methyl 3-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-
-benzoate;
2-[3-(acetylamino)phenyl]-N-{[4-(3-fluorobenzyl)morpholin-2-yl]methyl}-
-acetamide;
N-{[4-(3-fluorobenzyl)morpholin-2-yl]methyl}-2-{4-[(methylsulfonyl)-
-amino]phenyl}acetamide;
2-[3-(acetylamino)phenyl]-N-{[4-(3,4-difluorobenzyl)morpholin-2-yl]methyl}-
-acetamide;
N-{[4-(3,4-difluorobenzyl)morpholin-2-yl]methyl}-2-{4-[(methylsulfonyl)-
-amino]phenyl}acetamide;
2-[4-(acetylamino)phenyl]-N-{[4-(3,4-difluorobenzyl)morpholin-2-yl]-
-methyl}acetamide;
N-{[4-(3,4-difluorobenzyl)morpholin-2-yl]methyl}-2-{3-[(methylsulfonyl)-
-amino]phenyl}acetamide;
N-{[4-(3,4-difluorobenzyl)morpholin-2-yl]methyl}-2-[3-(methylsulfonyl)-
-phenyl]acetamide;
N-{[4-(3-chlorobenzyl)morpholin-2-yl]methyl}-2-[4-(methylsulfonyl)-
-phenyl]acetamide;
N-{[4-(3-chlorobenzyl)morpholin-2-yl]methyl}-2-[3-(methylsulfonyl)-
-phenyl]acetamide;
2-[3-(acetylamino)phenyl]-N-{[4-(4-fluorobenzyl)morpholin-2-yl]methyl}acetamide;
N-{[4-(4-fluorobenzyl)morpholin-2-yl]methyl}-2-{4-[(methylsulfonyl)amino]-
-phenyl}acetamide;
2-[4-(acetylamino)phenyl]-N-{[4-(4-fluorobenzyl)morpholin-2-yl]methyl}acetamide;
N-{[4-(2,3-dichlorobenzyl)morpholin-2-yl]methyl}-2-[4-(methylsulfonyl)-
```

2-[3-(acetylamino)phenyl]-N-{[4-(2,3-dichlorobenzyl)morpholin-2-yl]methyl}-

```
Application No. PCT/EP03/03348
Attorney Docket No. PG4788USW
-acetamide;
N-{[4-(2,3-dichlorobenzyl)morpholin-2-yl]methyl}-2-{4-[(methylsulfonyl)-
-amino]phenyl}acetamide;
N-{[4-(2,3-dichlorobenzyl)morpholin-2-yl]methyl}-2-(4-{[(methylamino)-
-carbonyl]amino}phenyl)acetamide;
N-({4-[(5-chlorothien-2-yl)methyl]morpholin-2-yl}methyl)-2-[4-(methylsulfonyl)-
-phenyl]acetamide;
2-[3-(acetylamino)phenyl]-N-({4-[(5-chlorothien-2-yl)methyl]morpholin-2-
-yl}methyl)acetamide;
N-({4-[(5-chlorothien-2-yl)methyl]morpholin-2-yl}methyl)-2-{4-[(methylsulfonyl)-
-amino]phenyl}acetamide;
N-({4-[(5-chlorothien-2-yl)methyl]morpholin-2-yl}methyl)-2-{3-[(methylsulfonyl)-
-amino]phenyl}acetamide;
2-[3-(acetylamino)phenyl]-N-{[4-(3-chlorobenzyl)morpholin-2-yl]methyl}-
-acetamide;
N-{[4-(3-chlorobenzyl)morpholin-2-yl]methyl}-2-{4-[(methylsulfonyl)-
-amino]phenyl}acetamide;
2-[4-(acetylamino)phenyl]-N-{[4-(3-chlorobenzyl)morpholin-2-yl]methyl}-
-acetamide;
N-{[4-(3-chlorobenzyl)morpholin-2-yl]methyl}-2-(4-{[(methylamino)carbonyl]-
-amino) phenyl) acetamide;
2-[4-(acetylamino)phenyl]-N-{[4-(2,3-dichlorobenzyl)morpholin-2-yl]-
-methyl}acetamide;
N-{[4-(2,3-dichlorobenzyl)morpholin-2-yl]methyl}-2-[3-(methylsulfonyl)-
-phenyl]acetamide;
```

2-[4-(aminosulfonyl)phenyl]-N-{[4-(3,4-dichlorobenzyl)morpholin-2-

-yl]methyl}acetamide;

2-[2-(acetylamino)phenyl]-N-{[4-(3,4-dichlorobenzyl)morpholin-2-

-yl]methyl}acetamide;

2-(3-cyanophenyl)-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(2-fluorophenyl)acetamide;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(2,3-difluorophenyl)--acetamide;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(2,4-difluorophenyl)-

```
-acetamide;
```

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(2,5-difluorophenyl)-acetamide;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(2,6-difluorophenyl)-acetamide;

N-cyclopropyl-3-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2--oxoethyl]benzamide;

3-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-N-(2-methoxyethyl)benzamide;

3-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-N--ethylbenzamide;

3-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-N,N-dimethylbenzamide;

3-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-N-[2-(dimethylamino)ethyl]benzamide;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-{3-[(4-methylpiperazin-1-yl)carbonyl]phenyl}acetamide;

2-(3-aminophenyl)-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide;

2-(4-aminophenyl)-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide;

2-[4-(acetylamino)phenyl]-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-acetamide;

N-{4-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-phenyl}2-methylpropanamide;

N-{3-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-phenyl}2-methylpropanamide;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-{3-[(methylsulfonyl)-amino]phenyl}acetamide;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-{4-[(methylsulfonyl)-amino]phenyl}acetamide;

N-{3-[2-({[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-phenyl}-2-(dimethylamino)acetamide;

2-{4-[bis(methylsulfonyl)amino]phenyl}-N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-[3-(methylsulfonyl)-

```
-phenyl]acetamide;
```

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-[4-(methylsulfonyl)-2-nitrophenyl]acetamide;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-(2-hydroxyphenyl)acetamide;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-{4-[methyl(methylsulfonyl)-amino]phenyl}acetamide;

N-{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-{3-[methyl(methylsulfonyl)-amino]phenyl}acetamide;

2-[2-amino-4-(methylsulfonyl)phenyl]-N-{[4-(3,4-dichlorobenzyl)morpholin-2--yl]methyl}acetamide;

N-({(2S)-4-[(5-chlorothien-2-yl)methyl]morpholin-2-yl}methyl)-2-{3-

-[(methylsulfonyl)amino]phenyl}acetamide;

N-({(2R)-4-[(5-chlorothien-2-yl)methyl]morpholin-2-yl}methyl)-2-{3-

-[(methylsulfonyl)amino]phenyl}acetamide;

N-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-{4-[(methylamino)-sulfonyl]phenyl}acetamide;

N-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-{4-[(ethylamino)-sulfonyl]phenyl}acetamide;

2-[3-(aminosulfonyl)phenyl]-N-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}acetamide;

2-{3-[(cyclopropylamino)sulfonyl]phenyl}-N-{[(2S)-4-(3,4-dichlorobenzyl)-morpholin-2-yl]methyl}acetamide;

N-{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl}-2-{3-[(ethylamino)-sulfonyl]phenyl}acetamide;

 $N-\{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl\}-2-\{3-[(methylamino)-sulfonyl]phenyl\}acetamide;$ 

N-{[(2S)-4-(4-fluorobenzyl)morpholin-2-yl]methyl}-2-{4-[(methylsulfonyl)-amino]phenyl}acetamide;

N-{[(2R)-4-(4-fluorobenzyl)morpholin-2-yl]methyl}-2-{4-[(methylsulfonyl)-amino]phenyl}acetamide;

2-[4-(aminosulfonyl)phenyl]-N-{[4-(3,4-dichlorobenzyl)morpholin-2-

-yl]methyl}acetamide;

 $2-\{4-[(cyclopropylamino)sulfonyl]phenyl\}-N-\{[4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl\} acetamide; \\$ 

N-cyclopropyl-3-[2-({[(2S)-4-(2,3-dichlorobenzyl)morpholin-2-yl]methyl}amino)-2--oxoethyl]benzamide;

3-{2-[({(2S)-4-[(5-chlorothien-2-yl)methyl]morpholin-2-yl}methyl)amino]-2-oxoethyl}-N-cyclopropylbenzamide;

N-cyclopropyl-3-[2-({[(2S)-4-(4-fluorobenzyl)morpholin-2-yl]methyl}amino)-2--oxoethyl]benzamide;

3-[2-({[(2S)-4-(3-chlorobenzyl)morpholin-2-yl]methyl}amino)-2-oxoethyl]-N--cyclopropylbenzamide;

N-cyclopropyl-3-[2-({[(2S)-4-(3,4-difluorobenzyl)morpholin-2-yl]methyl}amino)-2--oxoethyl]benzamide, and;

 $N-cyclopropyl-3-[2-(\{[(2S)-4-(3,4-dichlorobenzyl)morpholin-2-yl]methyl\}amino)-2--oxoethyl] benzamide. \\$ 

- 2. (Original) A compound of formula (I) according to claim 1 wherein  $R^1$  is unsubstituted or substituted phenyl.
- 3. (Currently amended) A compound of formula (I) according to claim 1 er claim 2 wherein R<sup>1</sup> is unsubstituted phenyl or phenyl substituted with 4-(methanesulphonyl), 4-(methylcarbonylamino), 2,4,6-(trifluoro), 3-(methylthio), 2,5-(difluoro), 4-(pyrazol-1-yl), 3-(methanesulphonyl), 3-(2-methyl-1,3,4-oxadiazol-5-yl), 3-(1,3,4-oxadiazol-5-yl), 3-(2-methyl-1,3,4-triazol-5-yl), 4-(ethylcarbonylamino), 4-(methylaminocarbonyl), 4-(carboxy), 3-(iso-propanesulphonylamino), 3-(cyclopropanesulphonylamino), 3-(ethanesulphonylamino), 4-(methylaminocarbonylamino), 4-methanesulphonyl-2-methanesulphonylamino), 4-(ethylaminocarbonyl), 3-(N,N-dimethylaminosulphonyl), 4-(methanesulphonylaminomethyl), 3-(methanesulphonylamino), 3-(cyclopropylcarbonyl), 3-(methylcarbonyl), 3-(methoxycarbonyl), 3-(aminosulphonyl), 4-(methanesulphonylamino), 3-(methylaminocarbonyl), 3-(dimethylaminocarbonyl), 3-(iso-propylaminocarbonyl), 3-(isopropylmethylaminocarbonyl), 4-(fluoro), 3-(amino), 4-(methylcarbonylamino), 3-(cyclopropylaminocarbonyl), 3-(methylcarbonylamino), 3-(ethylaminocarbonyl), 4-(piperidin-1-ylcarbonyl), 3-(ethoxycarbonyl), 4-cyano, 4-(aminosulphonyl), 4-(amido), 4-(chloro), or 3-(carboxy).

- 4. (Currently amended) A compound of formula (I) according to any one of the preceding claims claim 1 wherein  $R_{na}$  and  $R_{nb}$  are both hydrogen.
- 5. (Currently amended) A compound of formula (I) according to any one of the preceding claims claim 1 wherein n is 1, 2, or 3.
- 6. (Currently amended) A compound of formula (I) according to any one of the preceding claims claim 1 wherein R<sup>10</sup> is hydrogen or methyl.
- 7. (Currently amended) A compound of formula (I) according to any one of the preceding claims claim 1 wherein R<sup>10</sup> is hydrogen.
- 8. (Currently amended) A compound of formula (I) according to any one of the preceding claims claim 1 wherein R<sup>3</sup> is hydrogen.
- 9. (Currently amended) A compound of formula (I) according to any one of the preceding claims claim 1 wherein R<sup>2</sup> is unsubstituted or substituted phenyl, unsubstituted or substituted pyridinyl.
- 10. (Currently amended) A compound of formula (I) according to any one of the preceding claims claim 1 wherein R<sup>2</sup> is phenyl substituted with chloro or fluoro, thiophenyl substituted with chloro, or pyridinyl.
- 11. (Currently amended) A compound of formula (I) according to any one of the preceding claims claim 1 wherein R<sup>2</sup> is 3-fluorophenyl, 4-fluorophenyl, 2,5-dichlorophenyl, 3-chlorophenyl, 3-(trifluoromethyl)phenyl, 3-chlorophenyl, 3,4-difluorophenyl, 3-chloro-4-fluoro-phenyl, 2-chlorothiophen-5-yl, or pyridin-3-yl.

## 12. - 15. (Cancelled)

16. (Original) A process for the preparation of a compound of formula (I) as defined in claim 1 which process comprises the reaction of a compound of formula (II) with a compound of formula (III);

wherein;

R<sup>1</sup>, X, Y, R<sup>3</sup>, R<sup>10</sup>, and R<sup>2</sup> are as hereinbefore defined for formula (I) in claim 1, in the presence of a peptide coupling agent, and, if necessary, an activating agent and thereafter, if required, carrying out one or more of the following optional steps:

- (i) converting a compound of formula (I) to a further compound of formula (I);
- (ii) removing any necessary protecting group;
- (iii) preparing a salt or solvate of the compound so formed.

17. (Original) A process for the preparation of a compound of formula (I) which process comprises reaction of a compound of formula (XI) with a compound of formula (III);

$$R^{1}$$
 $X$  $Y$  $L^{2}$  $(XI)$ 

wherein  $L^2$  is a leaving group, and  $R^1$ , X, and Y are as hereinbefore defined for formula (I) in claim 1, and thereafter, if required, carrying out one or more of the following optional steps:

- (i) converting a compound of formula (I) to a further compound of formula (I);
- (ii) removing any necessary protecting group;
- (iii) preparing a salt or solvate of the compound so formed.

## 18. (Original) A compound of formula (IIIBE)

Application No. PCT/EP03/03348 Attorney Docket No. PG4788USW

$$\begin{array}{c|c} A & OH & OH \\ \hline & N & R^{10} \\ \hline & R^2 & (IIIBE) \end{array}$$

wherein R<sup>2</sup> and R<sup>10</sup> are as defined for formula (I) in claim 1 and A is a protected amino group.

19. (Original) A compound of formula (IIIBR)

wherein  $R^2$  and  $R^{10}$  are as defined for formula (I) in claim 1 and A is a protected amino group.

- 20. (Original) A compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof for use as an active therapeutic agent.
- 21. (Currently amended) A compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, for use in the treatment of inflammatory conditions, e.g. asthma or rhinitis.
- 22. (Currently amended) A method of manufacture of a medicament for the treatment of inflammatory conditions comprising incorporating Use of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof for the manufacture of a in said medicament for the treatment of inflammatory conditions, eg. asthma or rhinitis.
- 23. (Currently amended) A method for the treatment of a human or animal subject suffering from or susceptible to an inflammatory condition e.g. asthma or

Application No. PCT/EP03/03348 Attorney Docket No. PG4788USW

rhinitis, which method comprises administering an effective amount of a compound of formula (I) as defined in claim 1 or a physiologically acceptable salt or solvate thereof.

24. (Original) A pharmaceutical composition comprising a compound of formula (I) as defined in claim 1, or a physiologically acceptable salt or solvate thereof, and optionally one or more physiologically acceptable diluents or carriers.